Clinical Study of UX701 AAV-Mediated Gene Transfer for the Treatment of Wilson Disease

Learn more about:
Related Clinical Trial
Gandouling in the Treatment of Wilson’s Disease International Wilson’s Disease Patient Registry (iWilson Registry) Wilson France Register Study of ALXN1840 Versus Standard of Care in Pediatric Participants With Wilson Disease Clinical Features and Outcome of Wilson’s Disease With Generalized Epilepsy in Chinese Patients Role for Biochemical Assays and Kayser-Fleischer Rings in Diagnosis of Wilson Disease rTMS in Wilmson Diasease Dysarthria Adeno-Associated Virus (AAV) Antibody Study in Subjects OTC Deficiency, GSDIa, and Wilson Disease Clinical Study of UX701 AAV-Mediated Gene Transfer for the Treatment of Wilson Disease Copper and Molybdenum Balance in Participants With Wilson Disease Treated With ALXN1840 A Phase I/II Study of VTX-801 in Adult Patients With Wilson’s Disease Study of ALXN1840 on the Metabolism of a CYP2B6 Substrate in Healthy Participants Phase 1 Study of ALXN1840 on the Metabolism of a CYP2C9 Substrate in Healthy Participants. Clinical Evaluation and Assessment of Instruments and Biomarkers in Subjects With Wilson Disease Copper Concentration and Histopathologic Changes in Liver Biopsy in Participants With Wilson Disease Treated With ALXN1840 Study of Retinal Vascular Parameters in Patients With Wilson’s Disease Evaluation of Patients With Liver Disease ExAblate Transcranial MRgFUS for the Management of Treatment-Refractory Movement Disorders The Assessment of Copper Parameters in Wilson Disease Subjects on Standard of Care Treatment Establishment of Human Cellular Disease Models for Wilson Disease Efficacy and Safety, Long-term Study of Zinc Acetate to Treat Wilson’s Disease in Japan. Study to Assess Long-Term Outcomes of Trientine in Wilson Disease Patients Withdrawn From Therapy With d-Penicillamine A Controlled Study of Potential Therapeutic Effect of Oral Zinc in Manifesting Carriers of Wilson Disease Plasma Exchange and Continuous Hemodiafiltration in Treatment of Wilson’s Disease-related Liver Failure The Individual Therapy for Patients With Wilson’s Disease Study of Zinc for Wilson Disease Trientine Tetrahydrochloride (TETA 4HCL) for the Treatment of Wilson’s Disease Study of Tetrathiomolybdate in Patients With Wilson Disease Efficacy and Safety of ALXN1840 (Formerly Named WTX101) Administered for 48 Weeks Versus Standard of Care in Patients With Wilson Disease With an Extension Period of up to 60 Months WILSTIM – DBS (WILson STIMulation – Deep Brain Stimulation) Efficacy and Safety Study of Zinc Acetate to Treat Wilson’s Disease in Japan. Efficacy of Invitro Expanded Bone Marrow Derived Allogeneic Mesenchymal Stem Cell Transplantation Via Portal Vein or Hepatic Artery or Peripheral Vein in Patients With Wilson Cirrhosis Inhibitory rTMS in Dystonic Wilson Patients Natural History of Wilson Disease A Registered Cohort Study on Wilson’s Disease sCD163 and sMR in Wilsons Disease – Associations With Disease Severity and Fibrosis Cohort Research on Wilson’s Disease Single Daily Dosage of Trientine for Maintenance Treatment for Wilson Disease A Phase 1 Study to Assess the Effects in the Body of a Single Dose of Trientine Dihydrochloride in Wilson’s Disease Patients Efficacy and Safety Study of WTX101 in Adult Wilson Disease Patients

Brief Title

Clinical Study of UX701 AAV-Mediated Gene Transfer for the Treatment of Wilson Disease

Official Title

A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Seamless, Adaptive, Safety, Dose-Finding, and Phase 3 Clinical Study of UX701 AAV-Mediated Gene Transfer for the Treatment of Wilson Disease

Brief Summary

      The primary objectives of this study are to evaluate the safety of single IV doses of UX701
      in patients with Wilson disease, to select the UX701 dose with the best benefit/risk profile
      based on the totality of safety and efficacy data and to evaluate the effect of UX701 on
      copper regulation.
    

Detailed Description

      This study is a randomized, double-blind, placebo-controlled, seamless, adaptive Phase 1/2/3
      clinical study of UX701 in patients with Wilson disease.

      Stage 1 (Phase 1/2) is designed to evaluate the safety and efficacy of 3 dose levels of UX701
      to establish initial safety of UX701 and select a safe and efficacious dose for further
      evaluation. Stage 2 (Phase 3) is designed to evaluate the safety and efficacy of UX701 using
      the dose selected in Stage 1. Stage 3 (long-term follow-up) is designed to evaluate the
      long-term safety, efficacy, and clinical benefit of UX701. All participants will be followed
      for at least 5 years from the time of UX701 administration.

      Participants who receive UX701 will receive prophylactic oral corticosteroids. Participants
      who receive placebo will receive placebo oral corticosteroids to maintain the study blind.
    

Study Phase

Phase 1/Phase 2

Study Type

Interventional


Primary Outcome

Incidence of Treatment-Emergent Adverse Events (TEAEs), Treatment-Emergent Serious Adverse Events (TESAEs), Treatment-Related TEAEs, and Treatment-Related TESAEs

Secondary Outcome

 Stage 2: Change in Ceruloplasmin Activity Levels from Baseline at Week 52, Evaluated for Superiority

Condition

Wilson Disease

Intervention

UX701

Study Arms / Comparison Groups

 Stage 1: UX701 Dose Level 1
Description:  Participants randomized to receive a single, peripheral intravenous (IV) infusion of UX701 at dose level 1 plus prophylactic oral corticosteroids.

Publications

* Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.

Recruitment Information


Recruitment Status

Genetic

Estimated Enrollment

90

Start Date

September 27, 2021

Completion Date

January 2031

Primary Completion Date

January 2026

Eligibility Criteria

        Key Inclusion Criteria:

          -  Confirmed diagnosis of Wilson disease

          -  Ongoing copper chelator (ie, penicillamine, trientine) and/or zinc therapy for at
             least 12 months at screening, with no medication or dose changes for at least 6 months
             at screening.

          -  Stable Wilson disease as evidenced by stable laboratory values during the Screening
             Period

          -  Ongoing restriction of high copper containing foods for at least 12 months at
             Screening, continued through study participation.

          -  Willing and able to comply with all study procedures and requirements, including
             frequent blood collection, total urine collection over a 24-hour period,
             patient-reported outcome assessments, and long-term follow-up

        Key Exclusion Criteria:

          -  Detectable pre-existing antibodies to the AAV9 capsid.

          -  Stage 1 only: History of copper chelator or zinc therapy noncompliance, in the
             Investigator's judgment, within 12 months prior to Screening.

          -  History of liver transplant.

          -  Decompensated hepatic cirrhosis or presence of advanced liver disease as evidenced by
             portal hypertension, ascites, splenomegaly, esophageal varices, hepatic
             encephalopathy, or a liver biopsy with evidence of stage III fibrosis.

          -  Significant hepatic inflammation as evidenced by imaging or any of the laboratory
             abnormalities.

          -  Model for End-Stage Liver Disease (MELD) score > 13.

          -  Wilson Index score > 11

          -  Hemoglobin < 9 g/dL

          -  History of prolonged QT syndrome (QT interval > 450 msec on electrocardiogram [ECG])

          -  Presence of Stage 3 or higher chronic kidney disease based on estimated glomerular
             filtration rate < 60 mL/min/1.73 m2.

          -  Marked neurological deficit or compromise that, in the Investigator's opinion, would
             interfere with the subject's safety or ability to participate in the study.

          -  Moderate to severe depression, recent or active suicidal ideation with intent or
             suicidal behavior, psychosis, or unstable psychiatric illness.

          -  Participation in another gene transfer study or use of another gene transfer product
             before or during study participation.

          -  Subjects with known hypersensitivity to amide-containing local anesthetics are
             excluded from participating in the optional liver biopsy substudy.

        Note: Other protocol defined Inclusion/ Exclusion criteria may apply
      

Gender

All

Ages

18 Years - N/A

Accepts Healthy Volunteers

No

Contacts

Medical Director, 1-888-756-8657, [email protected]

Location Countries

Spain

Location Countries

Spain

Administrative Informations


NCT ID

NCT04884815

Organization ID

UX701-CL301

Secondary IDs

2020-005266-34

Responsible Party

Sponsor

Study Sponsor

Ultragenyx Pharmaceutical Inc


Study Sponsor

Medical Director, Study Director, Ultragenyx Pharmaceutical Inc


Verification Date

April 2022